ReviewDrugs2005
A critical appraisal of the role of insulin analogues in the management of diabetes mellitus.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 69 citations in OpenAlex.
- Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a pilot study.The Indian journal of medical research · 2012Trial
- Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes.Health and quality of life outcomes · 2006Trial
- Article
- Management of Hyperglycemia in Older Adults with Type 2 Diabetes.Drugs & aging · 2022Review
- Assessment of Insulin-related Knowledge among Healthcare Professionals in a Large Teaching Hospital in the United Kingdom.Pharmacy (Basel, Switzerland) · 2019Article
- Evidence-Based Management of Diabetes in Older Adults.Drugs & aging · 2018Review
- Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?Indian journal of endocrinology and metabolism · 2015Article
- Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2012Article
- Insulin therapy.Wiener medizinische Wochenschrift (1946) · 2011Review
- Special considerations with insulin therapy in older adults with diabetes mellitus.Drugs & aging · 2011Review
- Common crossroads in diabetes management.Osteopathic medicine and primary care · 2008Article
- Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs.MedGenMed : Medscape general medicine · 2007Review
- Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes.MedGenMed : Medscape general medicine · 2007Review
- Review
- Insulin detemir in the treatment of type 1 and type 2 diabetes.Vascular health and risk management · 2006Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin is one of the oldest and best studied treatments for diabetes mellitus. Despite many improvements in the management of diabetes, the nonphysiological time-action profiles of conventional insulins remain a significant obstacle. However, the advent of recombinant DNA technology made it possible to overcome these limitations in the time-action profiles of conventional insulins. Used as prandial (e.g. insulin lispro or insulin aspart) and basal (e.g. insulin glargine) insulin, the analogues simulate physiological insulin profiles more closely than the older conventional insulins. If rapid-acting insulin analogues are used in the hospital, healthcare providers will need a new mind-set. Any error in coordination between timing of rapid-acting insulin administration and meal ingestion may result in hypoglycaemia. However, guidelines regarding in-hospital use of insulin analogues are few. The safety profile of insulin analogues is still not completely established in long-term clinical studies. Several studies have shown conflicting results with respect to the tumourigenic potential of this new class of agents. The clinical implications of these findings are not clear. Although novel insulin analogues are promising 'designer drugs' in our armamentarium to overcome some of the limitations of conventional insulin therapy, cost may be a limiting factor for some patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.